Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.57 |
| ▸ | PLG | P00747 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7356254 | 1.00 | F2 (0.57) | F2PLGOPRM1OPRD1OPRK1 | |
| SCHEMBL6850981 | 1.00 | F2 (0.57) | F2PLGOPRM1OPRD1OPRK1 | |
| SCHEMBL7356276 | 1.00 | F2 (0.57) | F2PLGOPRM1OPRD1OPRK1 | |
| SCHEMBL27532662 | 1.00 | F2 (0.57) | F2PLGOPRM1OPRD1OPRK1 | |
| Acetic Acid SCHEMBL10728075 | 0.99 | F2 (0.56) | F2PLGOPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL11285878 | 0.99 | F2 (0.56) | F2PLGOPRM1OPRD1OPRK1 | |
| Sulfuric Acid SCHEMBL7264620 | 0.97 | F2 (0.54) | F2PLGOPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7304367 | 0.92 | OPRM1 (0.49) | F2PLGOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL7296655 | 0.90 | F2 (0.59) | F2PLGOPRM1OPRK1F10 | |
| SCHEMBL7395037 | 0.90 | F2 (0.53) | F2PLGOPRM1OPRK1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1025738-C | Process for preparing peptide-aldehydes and compositions thereof | INST MED PUBLIC ENTERPR (HU) | 1994-08-24 | — | — | CN | claimed |
| CN-85109736-A | Process for preparing peptide-aldehydes and compositions thereof | — | 1987-03-18 | — | — | CN | claimed |
| EP-3466961-B1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR | LI MIN (US) | 2022-04-06 | — | — | EP | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| WO-2001079195-A9 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INT INC (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6608204-B1 | Peptide aldehyde having arginine or arginine mimics at P1 and pyridone, pyrimidone, or uracil groups; antithrombosis agents | CORVAS INTERNATIONAL, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
| EP-0846682-B9 | PENICILLAMINAMIDE DERIVATIVES | MITSUBISHI CHEM CORP (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6541467-B1 | And at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. | CORVAS INTERNATIONAL, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6506761-B1 | Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506760-B1 | Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0508220-A1 | Derivatives of amindinophenylalanine, procedure for their preparation, their utilisation and compositions comprising them | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-10-14 | — | — | EP | disclosed |
| US-5153176-A | Substituted lysine-proline-arginine peptide | NITTO BOSEKI CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0185390-B1 | TRIPEPTIDYL-ARGININALDEHYDE, PROCESS FOR ITS PREPARATION AND MEDICAMENTS THEREOF, AS WELL AS N-(MONOALKYL) AND N,N-DI-(ALKYL)-XXX-L-PROLINE DIPEPTIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-10-02 | — | — | EP | disclosed |
| US-4703036-A | ANTICOAGULANTS | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1987-10-27 | — | — | US | disclosed |
| CN-85109736-A | Process for preparing peptide-aldehydes and compositions thereof | — | 1987-03-18 | — | — | CN | disclosed |
| US-4478745-A | ANTICOAGULANTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-10-23 | — | — | US | disclosed |
| US-4478745-A | ANTICOAGULANTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-10-23 | — | — | US | disclosed |
| US-4399065-A | AQUEOUS SOLUTION, NATICOAGULANT | PATENTBUREAU DANUBIA (HU) | 1983-08-16 | — | — | US | disclosed |
| US-4399065-A | AQUEOUS SOLUTION, NATICOAGULANT | PATENTBUREAU DANUBIA (HU) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | F2 1/4885PLG 13/4885OPRM1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.